These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36922934)

  • 1. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models.
    Phillips C; Bhamra I; Eagle C; Flanagan E; Armer R; Jones CD; Bingham M; Calcraft P; Edmenson Cook A; Thompson B; Woodcock SA
    Cancer Res Commun; 2022 Sep; 2(9):914-928. PubMed ID: 36922934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
    Shah K; Panchal S; Patel B
    Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
    Jiang X; Hao HX; Growney JD; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh MH; Bagdasarian L; Meyer R; Smith TR; Avello M; Charlat O; Xie Y; Porter JA; Pan S; Liu J; McLaughlin ME; Cong F
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12649-54. PubMed ID: 23847203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition.
    Flanagan DJ; Woodcock SA; Phillips C; Eagle C; Sansom OJ
    Pharmacol Ther; 2022 Oct; 238():108179. PubMed ID: 35358569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.
    Aguilera KY; Le T; Riahi R; Lay AR; Hinz S; Saadat EA; Vashisht AA; Wohlschlegel J; Donahue TR; Radu CG; Dawson DW
    Mol Cancer Ther; 2022 Jun; 21(6):936-947. PubMed ID: 35313331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.
    Picco G; Petti C; Centonze A; Torchiaro E; Crisafulli G; Novara L; Acquaviva A; Bardelli A; Medico E
    EMBO Mol Med; 2017 Mar; 9(3):293-303. PubMed ID: 28100566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.
    Yang Q; Qin T; An T; Wu H; Xu G; Xiang J; Lei K; Zhang S; Xia J; Su G; Wang D; Xue M; Kong L; Zhang W; Wu S; Li Y
    Eur J Pharmacol; 2023 Apr; 945():175628. PubMed ID: 36858339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
    Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
    BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
    Liu J; Pan S; Hsieh MH; Ng N; Sun F; Wang T; Kasibhatla S; Schuller AG; Li AG; Cheng D; Li J; Tompkins C; Pferdekamper A; Steffy A; Cheng J; Kowal C; Phung V; Guo G; Wang Y; Graham MP; Flynn S; Brenner JC; Li C; Villarroel MC; Schultz PG; Wu X; McNamara P; Sellers WR; Petruzzelli L; Boral AL; Seidel HM; McLaughlin ME; Che J; Carey TE; Vanasse G; Harris JL
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20224-9. PubMed ID: 24277854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
    Yu J; Yusoff PAM; Woutersen DTJ; Goh P; Harmston N; Smits R; Epstein DM; Virshup DM; Madan B
    Cancer Res; 2020 Dec; 80(24):5619-5632. PubMed ID: 33067269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer.
    Yamamoto D; Oshima H; Wang D; Takeda H; Kita K; Lei X; Nakayama M; Murakami K; Ohama T; Takemura H; Toyota M; Suzuki H; Inaki N; Oshima M
    J Pathol; 2022 May; 257(1):39-52. PubMed ID: 35040131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
    Katoh M
    Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
    Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
    Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
    Zhong Z; Sepramaniam S; Chew XH; Wood K; Lee MA; Madan B; Virshup DM
    Oncogene; 2019 Oct; 38(40):6662-6677. PubMed ID: 31391551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
    Steinhart Z; Pavlovic Z; Chandrashekhar M; Hart T; Wang X; Zhang X; Robitaille M; Brown KR; Jaksani S; Overmeer R; Boj SF; Adams J; Pan J; Clevers H; Sidhu S; Moffat J; Angers S
    Nat Med; 2017 Jan; 23(1):60-68. PubMed ID: 27869803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
    Fischer MM; Yeung VP; Cattaruzza F; Hussein R; Yen WC; Murriel C; Evans JW; O'Young G; Brunner AL; Wang M; Cain J; Cancilla B; Kapoun A; Hoey T
    Sci Rep; 2017 Nov; 7(1):15270. PubMed ID: 29127379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
    Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
    Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.